Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 11, 2014, Pages 1342-1344

  Wiegand, J ^a   Maasoumy, B ^b   Buggisch, P ^c   Buslau, A ^d   Schiefke, I ^e   Berg, T ^a   Wedemeyer, H ^b   Sarrazin, C ^d   Hinrichsen, H ^f  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Ifi Institute for Interdisciplinary Infectiology   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e Klinikum St Georg   (Germany)

^f Gastroenterologisch Hepatologisches Zentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; HEMOGLOBIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR;

ANAL COMPLAINT; ANEMIA; ANTIVIRAL ACTIVITY; ASTHENIA; CEREBROVASCULAR ACCIDENT; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; FEMUR FRACTURE; FLU LIKE SYNDROME; GENOTYPE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERTENSIVE CRISIS; LETTER; NONHUMAN; NOROVIRUS INFECTION; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE THERAPY;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 84900022838     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12748     Document Type: Letter

References (7)

1. Maasoumy B, Port K, Calle SB, et al,. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther 2013; 38: 1365-72.
2. Maasoumy B, Port K, Markova AA, et al,. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
3. Dumortier J, Guillaud O, Gagnieu MC, et al,. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56: 146-9.
4. Sclair S, Patel A, Junaidi O, et al,. Telaprevir or boceprevir therapy in chronic hepatitis C patients with end stage renal disease on hemodialysis is safe, tolerable and feasible. J Hepatol 2013; 58: 370-1.
5. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R,. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006; 13: 316-21.
6. Brennan BJ, Wang K, Blotner S, et al,. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother 2013; 57: 6097-105.
7. Kiser JJ, Burton JR Jr, Everson GT,. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606.